Bone volume, mineral density, and fracture risk after kidney transplantation

Satu Keronen1*1, Leena Martola1, Patrik Finne1, Inari S. Burton2, Xiaoyu F. Tong2, Heikki Kroger2,3, Eero Honkanen1

1 Department of Nephrology, Abdominal Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2 Kuopio Musculoskeletal Research Unit (KMRU), University of Eastern Finland, Kuopio, Finland, 3 Department of Orthopedics, Traumatology and Hand Surgery, Kuopio University Hospital, Kuopio, Finland

* satu.keronen@hus.fi

Abstract

Background
Disordered mineral metabolism reverses incompletely after kidney transplantation in numerous patients. Post-transplantation bone disease is a combination of pre-existing chronic kidney disease and mineral disorder and often evolving osteoporosis. These two frequently overlapping conditions increase the risk of post-transplantation fractures.

Material and methods
We studied the prevalence of low bone volume in bone biopsies obtained from kidney transplant recipients who were biopsied primarily due to the clinical suspicion of persistent hyperparathyroidism between 2000 and 2015 at the Hospital District of Helsinki and Uusimaa. Parameters of mineral metabolism, results of dual-energy x-ray absorptiometry scans, and the history of fractures were obtained concurrently.

One hundred nine bone biopsies taken at a median of 31 (interquartile range, IQR, 18–70) months after transplantation were included in statistical analysis. Bone turnover was classified as high in 78 (72%) and normal/low in 31 (28%) patients. The prevalence of low bone volume (n = 47, 43%) was higher among patients with low/normal turnover compared to patients with high turnover [18 (58%) vs. 29 (37%), P = 0.05]. Thirty-seven fragility fractures in 23 (21%) transplant recipients corresponding to fracture incidence 15 per 1000 person-years occurred during a median follow-up 9.1 (IQR, 6.3–12.1) years. Trabecular bone volume did not correlate with incident fractures. Accordingly, low bone mineral density at the lumbar spine correlated with low trabecular bone volume, but not with incident fractures. The cumulative corticosteroid dose was an important determinant of low bone volume, but not of incident fractures.

Conclusions
Despite the high prevalence of trabecular bone loss among kidney transplant recipients, the number of fractures was limited. The lack of association between trabecular bone volume
and fractures suggests that the bone cortical compartment and quality are important determinants of bone strength and post-transplantation fracture.

### Introduction

Bone volume, reflected by bone mineral density (BMD), as well as bone quality, contributes to bone strength which is altered in patients with chronic kidney disease (CKD). The risk of fractures increases with declining kidney function \[1,2\]. However, traditional risk factors of osteoporosis (e.g., increased age, diabetes, malnutrition, physical inactivity, hypogonadism, and smoking) account only partly for the excessive risk of fractures among the CKD population \[3–5\]. Bone turnover and mineralization, which are also important contributors to bone quality, are altered in almost all CKD patients.

In a large proportion of transplant recipients, pre-existing chronic kidney disease-mineral and bone disorder (CKD-MBD) reverses incompletely, especially with declined allograft function. Low bone formation due to immunosuppressive therapy, especially corticosteroids, further aggravates trabecular bone loss. These two often overlapping conditions increase the risk of post-transplantation fracture \[6–11\]. Besides the decreased quality of life, fractures increase the risk of hospitalization and mortality in transplant recipients \[12\].

Altered bone turnover is the primary target of the pharmacological treatment of CKD-MBD. Parathyroidectomy is considered in patients with hyperparathyroidism refractory to pharmacological treatment with vitamin D analogous either alone or combined with calcimimetics. However, antiresorptive or anabolic agents are required for the treatment of osteoporosis. Differentiation between these conditions is therefore necessary for the accurate treatment of the patient and to prevent consecutive fractures.

In the general population low bone volume and impaired mineralization are associated with an increased risk of fracture. The histomorphometric analysis of iliac crest bone biopsy has been selected as the most precise method to evaluate bone metabolism \[13\]. Bone biopsy, however, is infrequently performed due to its invasive nature and sample analysis requiring specific expertise. Bone quantity can also be measured for the assessment of BMD using areal dual-energy x-ray absorptiometry (DXA). Growing evidence suggests the utility of decreased BMD to predict fractures also in transplant recipients \[14–16\].

This retrospective bone biopsy-based study was conducted to evaluate the prevalence of low bone volume and fractures after kidney transplantation. Another aim of this study was to analyze the relationship between bone histomorphometry, DXA, and fractures in kidney transplant recipients.

### Materials and methods

After obtaining approval from the Research Ethics Board of the Division of Medicine, Helsinki University Central Hospital (approval no. 413/13/03/00/09) and Institutional Review Board of the Hospital District of Helsinki and Uusimaa (HUS/33/2010, HUS/269/2017 and HUS/333/2019) with a waiver of informed consent of medical record review, the medical records of transplant recipients referred for bone biopsy between January 1, 2000, and December 31, 2015, were retrospectively screened. The flow chart of patients included in the study is presented in Fig 1. Thirteen repeat biopsies of 136 biopsies were excluded. The parameters of turnover and bone volume were determined in 109 patients, who were included in statistical analysis.
The clinical and research activities reported here are consistent with the Principles of the Declaration of Istanbul as outlined in the ’Declaration of Istanbul on Organ Trafficking and Transplant Tourism’.

**Data collection**

We reviewed electronic patient charts between September 30, 2019, and March 1, 2021, for relevant demographics (age, sex, medical comorbidities, fractures, previous parathyroidectomy, and mineral metabolism therapy at the time of biopsy) and laboratory findings. Data for prevalent (before transplantation) and incident fractures were collected from hospital records including surgery reports and documents of imaging examinations. Outpatient documents were not, however, available. Spine X-rays for screening asymptomatic vertebral fractures were not obtained. The localization and mechanism of injury were identified and fractures with documented prior trauma were excluded. The cohort entry date was the date of bone biopsy (between May 18, 2000, and October 5, 2015). Patients were followed until the return to maintenance dialysis, death, or the end of follow-up (December 31, 2019). The follow-up data varied between August 30, 2002, and December 31, 2019.

Plasma inorganic phosphate and ionized calcium, alkaline phosphatase (ALP), parathyroid hormone (PTH), plasma creatinine, and estimated glomerular filtration rate (eGFR) measured by the Chronic Kidney Disease Epidemiology Collaboration equation [17] were recorded at the time of or within three months preceding the bone biopsy. PTH at the time of transplantation was also available in a subset of patients. Plasma inorganic phosphate (reference range 0.71–1.41 mmol/l) was analyzed by photometric determination with Modular E170 analyzer (catalog number 1730347, Roche Diagnostics, Indianapolis, IN), while ionized calcium (reference range 1.16–1.3 mmol/l/pH 7.4) was analyzed by direct ion-selective electrode method with Radiometer ABL800 analyzer (Radiometer Medical). ALP was measured by enzyme-
linked immunosorbent assay (BM systems ALP between 2000 and October 2005 and since November 2005 ALP IFCC liquid) with Modular E170 analyzer (Roche Diagnostics, Indianapolis, IN). The reference range was 60–275 U/l until April 28, 2004, and since April 29, 2004, 35–105 U/l. Between 1998 and May 14, 2000, serum intact PTH levels (reference range 15–60 ng/l) were studied by immunoradiometric assay (INTACT PTH, catalog number 40–2170, Nichols Institute Diagnostics, San Juan Capistrano, CA). LIAISON (DiaSorin, Stillwater, MN) analyzer with immunoradiometric assay by Nichols (reference range 15–60 ng/l) was used to study intact plasma PTH levels between May 15, 2000, and September 9, 2001. Immunochemiluminometric assay (Immulite 2000 intact PTH, catalog number L2KPP2, reference range 15–73 ng/l) and Immulite 2000 Systems analyzer (Siemens Healthcare Diagnostics) was used from September 10, 2001, to May 31, 2011. Since June 1, 2011, electrochemiluminescence immunoassay (reference range 12–47 ng/l) with Modular E170 analyzer (Roche Diagnostics, Indianapolis, IN) was used. Since January 15, 2014, the reference range for the same method was changed to 15–65 ng/l. All assays were performed according to manufacturers’ instructions at HUS-LAB, at Meilahti laboratory, Helsinki, Finland.

**Bone biopsy and histomorphometric analysis**

Iliac crest bone biopsies were obtained 5–14 days after the second labeling with tetracycline (500 mg 3 times/day over two separate 2-day periods with a 10-day interlabel time) and under local anesthesia. Bone biopsied were obtained with a drill (Straumann, Switzerland) until the year 2005 and thereafter the vertical technique by 8G – 11G needle (T-Lok, Angiotech, Reading, PA, USA) was used.

The technique for quantitative histomorphometry has been described previously [18]. A semiautomatic image analyzer [Osteoplan II system (Carl Zeiss, Thornwood, NY) until the year 2004 and thereafter BioquantOsteoII (Bioquant Image Analysis Corporation, Nashville, TN, USA)] were used for performing histomorphometric analyses at standardized sites in the trabecular bone at x200 magnification.

Bone turnover was determined by the bone formation rate per bone surface (BFR/BS, normal reference value 18–38 μm3/μm2/year) and activation frequency (Ac.F, normal reference value 0.49–0.72/year) [19]. In the absence of tetracycline labeling, or if only a single label was found in the trabecular bone area, the assessment of bone turnover was made using osteoblastic (Ob.S/BS, %) and osteoclastic surfaces (Oc.S/BS, %). The reference values were applied as Z-scores based on Rehman et al. [20]. Mineralization was identified as abnormal when osteoid surface/bone surface (OS/BS, %) was more than ±2 SD compared with the mean value [19] and/or mineralization lag time (Mlt, days) exceeded 100 days [21]. The normal range of trabecular bone volume/tissue volume (BV/TV) was 16.8–22.9% [20]. The final classification of bone turnover and volume, however, was not based entirely on bone histomorphometric parameters, but on the consensus statement of two experienced histomorphometrists (HK, IB) also.

**Bone densitometry**

DXA scans taken during the preceding 12 months of the bone biopsy were included, while scans taken following 12 months after biopsy were included only if no interventions were done after the biopsy.

Until the year 2009 Hologic QDR 4500W scanner (Hologic, Marlborough, MA) and thereafter Lunar Prodigy scanner (GE Healthcare, Little Chalfont, UK) were used for the measurements of BMD at the lumbar spine and femoral neck. The coefficients of variation for DXA measurements were at lumbar spine 1% and femoral neck 1.5%. The BMD values were given...
in g/cm$^2$, and individual patient’s results were expressed as T-scores. Osteopenia was defined as a T-score between -1 and -2.5 and osteoporosis as a T-score -2.5 and below.

**Statistical analysis**

The results were reported according to STROBE statement guidelines for observational studies. We divided bone biopsy findings into two groups according to bone volume (low or normal) for statistical analysis. Bone turnover and mineralization were determined according to turnover-mineralization-volume classification. To compare PTH values at different time points, we used the conversion equations $y$(LIAISON) = 1.13$(IRMA)$ + 9 ($R = 0.98$), $y$(IMMULITE2000) = 0.99$(LIAISON)$ - 0.6 ($R = 0.98$) and $y$(Modular) = 0.52$(IMMULITE2000)$ + 11 ng/l. To allow comparisons between ALP values at different time points, we converted levels of ALP taken between January 1, 2000, and 28 April 28, 2004, by using the conversion equation $y =$ ALP (old)$^*$0.48. We imputed nine ALP values using the k-nearest neighbor approach [22]. The variables used for imputation were sex, age, the time between transplantation and bone biopsy, dialysis vintage, previous parathyroidectomy, bone turnover class, and the levels of ionized calcium and PTH. In 12 patients with only plasma total calcium level available, we converted levels of total calcium to ionized Ca by multiplying with 0.52. To compare differences in parameters between volume and fracture groups, we used Mann-Whitney U-test and Chi-square test for continuous and categorical variables, respectively. Kendall’s tau correlation coefficient was applied to determine correlations between continuous variables [23]. We performed all analyses with SPSS for Windows (version 25, SPSS, Chicago, IL, USA). All values are presented as the median and interquartile range (IQR, 25–75 percentiles) and number with percentage for nominal data. Statistical significance was defined as a two-sided P-value lower than 0.05.

**Results**

**The characteristics of transplant recipients**

In total, 109 biopsies (>95% white) were included in the statistical analysis. The indications for bone biopsy were hypercalcemia combined with elevated PTH levels in 68 (62%) patients and normocalcemia with elevated PTH levels in 38 (35%) patients, respectively. In one patient biopsy was obtained due to multiple fractures and in two patients due to isolated hypercalcemia.

The diagnosis of kidney disease was diabetic nephropathy in 23 (21%), polycystic kidney disease in 20 (18%), glomerulonephritis in 28 (26%), tubulointerstitial disease in 7 (6%), and hypertension/vascular in 4 (4%) patients. Twenty-seven (25%) patients had miscellaneous/other diseases.

Biopsies were taken at a median of 31 (IQR, 18–70) months after kidney transplantation. The median follow-up time was 9.1 (IQR, 6.3–12.1) years.

No data on hypogonadism was available. However, considering the median age of transplant recipients (53, IQR, 46–62 years) and that menopause is documented to occur 5 years earlier among women with advanced kidney failure compared to the general population [24], we presumed that most women included in this study were postmenopausal.

**The characteristics of transplant recipients with low bone volume**

The distribution of low bone volume and fractures is displayed in Fig 2. Bone volume was low in 47 (43%) transplant recipients. Bone turnover was classified as high in 78 (72%) and normal/low in 31 (28%) patients. The prevalence of low bone volume was higher among patients
with low/normal turnover compared to patients with high turnover [18 (58%) vs. 29 (37%),
P = 0.05]. The proportion of patients with impaired mineralization (19%) was similar in both
volume groups.

The characteristics and details of mineral metabolism therapy of transplant patients with or
without low bone volume in the bone biopsy are shown in Table 1. The maintenance

![Figure 2](https://doi.org/10.1371/journal.pone.0261686.g002)

**Table 1.** Characteristics of the transplant patients with or without low bone volume in bone biopsy.

| Characteristic                        | All transplant recipients n = 109 | Recipients with low bone volume n = 47 | Recipients with normal bone volume n = 62 | P-value |
|--------------------------------------|-----------------------------------|----------------------------------------|------------------------------------------|---------|
| Female                               | 44(40)                            | 17(36)                                 | 27(44)                                   | 0.56    |
| Age (years)                          | 53(46–62)                         | 56(46–65)                              | 52(45–59)                                | 0.13    |
| Diabetes mellitus                    | 42(39)                            | 22(47)                                 | 20(32)                                   | 0.16    |
| Dialysis vintage before biopsy (months) n = 106 | 25(13–43)                         | 23(11–39)                              | 27(16–52)                                | 0.07    |
| Timing of bone biopsy from KTX (months) n = 108 | 31(18–70)                         | 45(21–80)                              | 24(17–52)                                | **0.02** |
| Body mass index, (kg/m²)             | 25(22–27)                         | 24(22–27)                              | 25(22–28)                                | 0.54    |
| Coronary artery disease              | 17(16)                            | 12(26)                                 | 5(8)                                     | **0.02** |
| Peripheral artery disease            | 13(12)                            | 10(21)                                 | 3(5)                                     | **0.02** |
| Smoking n = 107                      | 42(39)                            | 14(30)                                 | 28(45)                                   | 0.12    |
| Previous KTX                         | 12(11)                            | 4(9)                                   | 8(13)                                    | 0.55    |
| Previous PTX                         | 9(8)                              | 3(6)                                   | 6(10)                                    | 0.73    |
| Patients with incident (follow-up) fractures | 23(21)                            | 13(28)                                 | 10(16)                                   | 0.14    |
| Corticosteroid use                   | 107(98)                           | 46(98)                                 | 61(98)                                   | 1.00    |
| Cumulative corticosteroid dose (mg) n = 106 | 3091(2253–8794)                   | 5351(2649–10 972)                      | 2704(2209–6178)                          | **0.02** |
| Bisphosphonate use                   | 39(36)                            | 19(40)                                 | 20(32)                                   | 0.42    |
| Cinacalcet use                       | 7(6)                              | 1(2)                                   | 6(10)                                    | 0.14    |

Values are expressed as median + interquartile range (in parentheses) or number of patients (percentages in parentheses).

KTX, kidney transplantation; PTX, parathyroidectomy.

[https://doi.org/10.1371/journal.pone.0261686.t001](https://doi.org/10.1371/journal.pone.0261686.t001)
immunosuppressive therapy comprised a calcineurin inhibitor, corticosteroids, and an anti-metabolite. Median age, sex distribution (40% women), and the proportion of patients with diabetes (39%) were similar between volume groups. Thirty-six percent of patients were using bisphosphonates, with a median duration of 14 (IQR, 9–31) months preceding the biopsy. Patients with low bone volume had more coronary and peripheral artery disease compared to patients with normal bone volume (26% vs. 8%, P = 0.02 and 21% vs. 5%, P = 0.02, respectively). Compared to patients with normal volume, the cumulative corticosteroid exposure was higher in patients with low bone volume [5351 (IQR, 2694–10 972) mg in low volume group vs. 2704 (IQR, 2209–6178) mg in the normal volume group, P = 0.02]. Among patients with low bone volume bone biopsy was taken almost two years later than in patients with normal volume [45 (IQR, 21–80) months vs. 24 (IQR, 17–52) months, P = 0.03]. The use of bisphosphonates was similar among different volume groups.

Laboratory values at the time of biopsy are displayed in Table 2. The kidney graft function was similar between volume and turnover groups with a median eGFR of 55ml/min (IQR, 45–72 ml/min). Median pre-transplantation PTH 265 (IQR, 169–421) ng/L did not differ between volume groups. Pre-biopsy PTH levels, however, were lower in patients with low bone volume compared to patients with normal volume [median PTH 126 (IQR, 96–184) ng/L, 105 vs. 147 ng/L P = 0.001].

Prevalent and incident fractures

The characteristics, biochemical, and bone histomorphometric as well as densitometry findings in patients with or without fractures are displayed in Table 3.

Four patients experienced a fracture before kidney transplantation. During the follow-up time, 37 fragility fractures occurred in 23 (21%) transplant recipients corresponding to fracture incidence of 15 per 1000 person-years. Eight (7%) patients experienced multiple fractures. One fracture was vertebral and 36 fractures were non-vertebral (hip 2, rib 4, leg 13 arm 14, and ankle 3).

Median time to the first fracture after transplantation was 7 (IQR, 1–12) months. Patients with fractures were a median of seven years younger than patients who did not experience a fracture. Neither gender, diabetes, BMI, smoking, dialysis vintage, the timing of the biopsy after transplantation, use of bisphosphonates nor history of the previous parathyroidectomy correlated with fractures. The cumulative corticosteroid exposure did not differ between patients with fractures or those without them (6178 mg vs. 3006 mg, P = 0.21). Median pre-transplantation PTH was, however, lower in patients with fractures compared to patients without them (177 vs. 326 ng/L, P = 0.007). Neither pre-biopsy PTH nor ALP levels correlated with fractures.
Bone histomorphometric parameters and fractures

Bone histomorphometric parameters among transplant recipients with or without low bone volume are shown in Table 4. Tetracycline labeling was found in 99 (91%) bone biopsies. Either Ob.S/BS, Oc.S/BS, or BFR were available in all included biopsies.

The distribution of bone turnover did not differ between patients with fractures and those without them. Accordingly, the proportion of patients with abnormal mineralization was similar in patients with fractures compared to those without them (22% vs. 19%).

### Table 4. Bone histomorphometric parameters in transplant recipients with and without low volume.

| Variable | All transplant recipients n = 109 | Transplant recipients with low volume n = 47 | Transplant recipients with normal volume n = 62 | P-value |
|----------|-----------------------------------|--------------------------------------------|-----------------------------------------------|---------|
| Bone formation rate/bone surface μm³/μm²/year | 16.79(7.30–29.20) | 10.73(6.53–21.90) | 21.9(10.95–42.24) | 0.005 |
| Activation frequency (1/yr) | 0.40(0.27–0.87) | 0.31(0.15–0.52) | 0.64(0.27–1.00) | 0.01 |
| Osteoid surface/bone surface % | 31.80(21.90–47.90) | 31.80(22.70–41.70) | 32.6(21.66–52.89) | 0.35 |
| Osteoblastic surface/bone % | 1.90(1.40–6.50) | 2.46(1.40–5.60) | 3.7(1.46–8.01) | 0.15 |
| Osteoclastic surface/bone % | 1.17(0–3.17) | 0.25(0–1.80) | 1.94(0–3.71) | 0.005 |
| Osteoid thickness μm | 8.4(6.6–11) | 7.30(6.1–10.6) | 9.2(6.7–11.7) | 0.05 |
| Mineralization lag time days n = 59 | 62.4(45.4–93.8) | 59.9(37.8–94.7) | 62.8(45.6–93.8) | 0.71 |
| Bone volume/tissue volume % | 20.1(14.5–26.3) | 13.2(10.5–16.6) | 25.6(21–30.5) | <0.001 |

Values are expressed as median + interquartile range (in parentheses). n = 22, n = 45, n = 17, n = 38, n = 20, n = 39.
The level of BV/TV did not differ between patients with fractures and those without them [18.1 (IQR, 16–25.8) % with fractures vs. 20.4 (IQR, 13.5–26.7) % without fractures, P = 0.47]. Ten (16%) patients with normal bone volume and 13 (28%) patients with low bone volume in bone biopsy experienced a fracture, but the difference did not reach statistical significance.

Bone mineral density

DXA measurements at the lumbar spine and femoral neck were available in 54 (50%) patients. Accordingly, DXA was available in 17 (74%) patients with fractures, respectively. DXA scan was obtained a median of two (IQR, nine months before to six months after) months before the biopsy. The use of bisphosphonates was more common in the DXA group (69% with DXA vs. 31% without DXA, respectively), but otherwise the characteristics or laboratory values of patients with DXA scan did not differ from patients without DXA scan.

The results of DXA measurements among transplant recipients with or without low bone volume are shown in Table 5.

The prevalence of osteoporosis and osteopenia at the lumbar spine and femoral neck according to World Health Organization criteria for DXA is displayed in Fig 3. The diagnostic overlap of low bone volume on the iliac bone biopsy and DXA scans is shown in Fig 4.

Discussion

In this bone biopsy-based study including mainly patients biopsied due to persistently elevated PTH levels, the prevalence of low bone volume was 43%. Applying WHO criteria for DXA scans, osteoporosis was present at different skeletal sites in 16–28% of the study population, while osteopenia was detected in 51–65% of the patients. During the median follow-up time of 9.1 years, 23 (21%) transplant recipients sustained fragility fractures corresponding to fracture incidence of 15 per 1000 person-years. Low volume in the bone biopsy was associated with coronary or peripheral artery disease but had no association with low bone volume detected in the bone biopsy, but did not associate with fractures. In the low bone volume group, the cumulative corticosteroid exposure was significantly higher compared to the normal volume group, at least partially due to the significantly later timing of bone biopsy from kidney transplantation.
In previous bone biopsy-based studies [25–31] in transplant recipients, the prevalence of low volume has ranged between 11% and 63%. Although the prevalence of low bone volume in this study is in agreement with earlier studies, they are poorly comparable primarily due to the...
significantly higher proportion of patients with high turnover in our study. Besides turnover, the wide variation in patient characteristics, the cumulative corticosteroid exposure, the proportion of patients using bisphosphonates, and the timing of the assessment of bone biopsy after transplantation differ significantly between studies. As previously has been noted [32,33], the cumulative corticosteroid dose affects inversely to bone volume.

The proportions of osteoporosis and osteopenia in DXA scans are consistent with data reported in preceding studies [14,15] despite notable differences in case mix and timing of DXA after kidney transplantation. In contrast to these previous studies, however, we could not find an association between DXA and fractures. This difference may be explained by the insufficient power due to the small number of DXA scans. Another possible explanation is the high proportion of patients with persistent hyperparathyroidism. According to the literature, the ability of BMD to predict fractures may vary across different levels of PTH [15,34]. Correlations between bone trabecular volume and DXA parameters gave inconsistent results. This is hardly surprising since DXA is a combined composite of both trabecular and cortical bone volume. Another possible explanation for the low correlation between bone volume and DXA is a variation in trabecular bone mass and microarchitecture of the iliac crest. As recently suggested by European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D [16], a widely adopted osteoporosis intervention threshold (-2.5) in BMD may be too low for patients with advanced CKD. The high prevalence of osteopenia in this study suggests that a higher BMD threshold may be more appropriate also for transplant recipients.

In consonance with previous studies, fractures in this study were predominantly peripheral [35]. The number of fractures in our study is substantially lower than in earlier reports [9] but is in agreement with studies in more recent cohorts [10,11,14,15]. In the general population, the estimated yearly incidence of fractures in Finland is 0.63%. As previously reported in the general population, also patients with normal bone volume experienced fractures in this study. The lack of correlation with BV/TV and fractures suggests that the pathogenesis of fracture after transplantation is complex and not associated entirely with bone volume. The impaired bone quality also increases the risk of fracture [2,36]. In the general population, decreased cortical thickness and increased porosity have been associated with increased fracture risk. In CKD patients data of the cortical component of bone is, however, limited [37–39]. In the study by Carvalho et al. [28], compared to the trabecular component, cortical bone was less affected by post-transplantation changes of mineral metabolism. In the course of the present study, however, the cortical component was not analyzed.

Bone turnover is also a significant contributor to bone strength. In CKD patients, both low and high turnover has been shown to associate with fracture risk [40]. The importance of bone turnover as a risk factor of fracture after kidney transplantation is somewhat ambiguous. In this study, lower PTH levels at the time of transplantation, perhaps implying low bone turnover, were associated with post-transplantation fractures. The distribution of turnover in this study was, however, similar in patients who experienced a fracture. The cumulative corticosteroid dose, previously shown to decrease bone formation and density, did not associate with fractures. The relatively short interval between the first fracture and transplantation may explain the lack of this association. It is clinically noteworthy, that in this study parathyroidectomy was done to almost half of the patients with verified high turnover. Nonetheless, our study design does not allow causalities to be established between post-transplantation parathyroidectomy and incident fractures. Although cinacalcet has been shown to increase BMD in transplant recipients [41], its role in preventing fractures after transplantation is unknown. However, in this study, the number of patients using cinacalcet was too limited to make definite conclusions.
Although there is variation in observation time and site of fractures included, putting our results into the context of existing literature, there is a general downward trend in the risk of post-transplantation fractures. The most plausible explanations for this favorable outcome are changes in immunosuppressive therapy, especially the use of steroid-sparing protocols, and restraining from excessive suppression of hyperparathyroidism during the maintenance dialysis.

Several strengths and limitations must be addressed. The main strength of this study is the availability of bone histomorphometric data combined with mineral metabolism parameters and data on previous and incident fractures in a substantial number of kidney transplant recipients. We were not able to find other histomorphometric studies in transplant recipients where bone fractures were used as an endpoint. In addition to the highly selected patient cohort, the absence of the analysis of cortical porosity, mainly mediated by increased bone turnover [36], may explain the lack of association between trabecular bone volume and fractures. Fractures were identified from hospital records and documents of imaging examinations, but outpatient documents were not available. It is thus possible that data on especially peripheral fractures is incomplete. In addition, it is plausible that data on previous asymptomatic vertebral fractures is lacking, because systematic screening of lumbar X-rays was not performed. During the study period, the levels of calcidiol were not systemically evaluated after kidney transplantation, thus the role of vitamin D deficiency either in the prevalence of low bone volume or fracture rate cannot be estimated. Comprehensive data on gonadal status as well as post-transplantation metabolic acidosis was missing. Despite these limitations, however, the high prevalence of trabecular bone loss in conjunction with DXA scans showing predominantly decreased BMD confirms the deterioration of bone volume after kidney transplantation.

The generalizability of the observations of the high prevalence of low bone volume but a limited number of fractures after kidney transplantation is hampered by the high percentage of patients with high bone turnover and identical ethnic backgrounds. In addition, the high proportion of patients with post-transplantation parathyroidectomy may affect the number of incident fractures. Despite the even distribution of fractures in different bone turnover groups, the presented results cannot be extrapolated to all transplant recipients.

To conclude, post-transplantation bone loss affects a great proportion of kidney transplant recipients. Although according to the literature, the number of post-transplantation fractures has declined significantly during the past decade, the incidence of fractures is still substantial compared to the general population. However, as stated by Ott [42], a bone biopsy is not presumably the best measure of bone volume, although it remains a necessary tool for the determination of bone turnover and mineralization [43]. The lack of association between bone trabecular volume and fractures warrants the need for further studies to evaluate the role of bone microarchitecture and bone cortical component in fractures of kidney transplant recipients.

Supporting information
S1 STROBE checklist. Checklist of items that should be included in reports of cohort studies.
(DOCX)

Acknowledgments
The authors acknowledge Dr. Helene Markkanen for her assistance in the comparison of PTH methods. Mr. Pasi Aronen from the Biostatistics Unit at the University of Helsinki is thanked for his great help with the imputation of ALP values.
Author Contributions

Conceptualization: Satu Keronen, Leena Martola, Patrik Finne, Inari S. Burton, Xiaoyu F. Tong, Heikki Kröger, Eero Honkanen.

Data curation: Satu Keronen, Leena Martola, Patrik Finne, Inari S. Burton, Eero Honkanen.

Formal analysis: Satu Keronen, Patrik Finne, Xiaoyu F. Tong.

Investigation: Satu Keronen, Inari S. Burton, Xiaoyu F. Tong, Heikki Kröger.

Methodology: Satu Keronen, Inari S. Burton, Xiaoyu F. Tong, Heikki Kröger.

Project administration: Eero Honkanen.

Software: Satu Keronen, Patrik Finne.

Supervision: Leena Martola, Patrik Finne, Eero Honkanen.

Validation: Inari S. Burton.

Visualization: Satu Keronen.

Writing – original draft: Satu Keronen, Leena Martola, Patrik Finne, Inari S. Burton, Xiaoyu F. Tong, Heikki Kröger, Eero Honkanen.

Writing – review & editing: Satu Keronen, Leena Martola, Patrik Finne, Inari S. Burton, Xiaoyu F. Tong, Heikki Kröger, Eero Honkanen.

References

1. Naylor KL, Garg AX, Zou G, Langsetmo L, Leslie WD, Fraser L, et al. Comparison of Fracture Risk Prediction among Individuals with Reduced and Normal Kidney Function. Clin J Am Soc Nephrol. 2015 Feb; 10(4):646–53. https://doi.org/10.2215/CJN.06040614 PMID: 25655423

2. Pimentel A, Ureña-Torres P, Zillikens MC, Bover J, Cohen-Solal M. Fractures in patients with CKD—diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. Kidney Int. 2017 Dec; 92(6):1343–55. https://doi.org/10.1016/j.kint.2017.07.021 PMID: 28964571

3. Leonard MB. A Structural Approach to Skeletal Fragility in Chronic Kidney Disease. Semin Nephrol. 2009 Mar; 29(2):133–43. https://doi.org/10.1016/j.semnephrol.2009.01.006 PMID: 19371904

4. Salam SN, Eastell R, Khwaja A. Fragility Fractures and Osteoporosis in CKD: Pathophysiology and Diagnostic Methods. Am J Kidney Dis. 2014 Jun; 63(6):1049–59. https://doi.org/10.1053/j.ajkd.2013.12.016 PMID: 24631043

5. McNemey EMB, Nickolas TL. Bone Quality in Chronic Kidney Disease: Definitions and Diagnostics. Curr Osteoporos Rep. 2017 Apr; 15(3):207–13. https://doi.org/10.1007/s11914-017-0366-z PMID: 28447312

6. Perrin P, Caillard S, Javier RM, Braun L, Heibel F, Bomi-Duval C, et al. Persistent Hyperparathyroidism Is a Major Risk Factor for Fractures in the Five Years After Kidney Transplantation. Am J Transplant. 2013 Oct; 13(10):2653–63. https://doi.org/10.1111/ajt.12425 PMID: 24034142

7. Hirukawa T, Kakuta T, Nakamura M, Fukagawa M. Mineral and bone disorders in kidney transplant recipients: reversible, irreversible, and de novo abnormalities. Clin Exp Nephrol. 2015 Aug; 19(4):543–55. https://doi.org/10.1007/s10157-015-1117-z PMID: 25931403

8. Altman A, Sprague S. Mineral and Bone Disease in Kidney Transplant Recipients. Curr Osteoporos Rep. 2018 Dec; 16(6):703–11. https://doi.org/10.1007/s11914-018-0490-4 PMID: 30390201

9. Nikkel LE, Hollenbeck CS, Fox EJ, Uemura T, Gahramani N. Risk of Fractures After Renal Transplantation in the United States. Transplantation. 2009 Jun 27; 87(12):1846–51. https://doi.org/10.1097/TP.0b013e3181a6bbda PMID: 19543063

10. Naylor K, Li A, Lam N, Hodson A, Jamal S, Garg A. Fracture Risk in Kidney Transplant Recipients: A Systematic Review. Transplantation. 2013 Jun 27; 95(12):1461–70. https://doi.org/10.1097/TP.0b013e31828eeaad8 PMID: 23594857

11. Perrin P, Kiener C, Javier R, Braun L, Cognard N, Gautier-Vargas G, et al. Recent Changes in Chronic Kidney Disease—Mineral and Bone Disorders and Associated Fractures After Kidney Transplantation.
12. Nair SS, Lenihan CR, Montez-Rath ME, Lowenberg DW, Chertow GM, Winkelmayer WC. Temporal Trends in the Incidence, Treatment and Outcomes of Hip Fracture After First Kidney Transplantation in the United States. Am J Transplant. 2014 Apr; 14(4):943–51. https://doi.org/10.1111/ajt.12652 PMID: 24712332

13. Dempster DW, Shane ES. Bone quantification and dynamics of bone turnover by histomorphometric analysis. Becker K.L. (Ed.), Principles and Practice of Endocrinology and Metabolism. 3rd Ed: Lippincott Williams and Wilkins, pp. 541–548; 2001.

14. Akaberi S, Simonsen O, Lindergård B, Nyberg G. Can DXA Predict Fractures in Renal Transplant Patients? Am J Transplant. 2008. Dec; 8(12):2647 –51. https://doi.org/10.1111/j.1600-6143.2008.02423.x PMID: 18853956

15. Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust M-L, et al. European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease. Nephrol Dial Transplant. 2020 Oct 24; 36(1):42–59.

16. Evenepoel P, Claes K, Meijers B, Laurent MR, Bammens B, Naesens M, et al. Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. Kidney Int. 2019 Jun; 95(6):127–34. https://doi.org/10.1016/j.kint.2018.12.024 PMID: 29332398

17. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, et al. A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 2009 May 5; 150(9):604 –12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006 PMID: 19414839

18. Kowarik A, Templ M. (2016). Imputation with the R Package # VIM. J Stat Softw. 2016 Oct; 74(7), 1–16.

19. Vellanki K, Hou S. Menopause in CKD. Am J Kidney Dis. 2018 May; 71 (5):710–19. https://doi.org/10.1053/j.ajkd.2017.12.019 PMID: 29530509

20. Borchhardt K, Sulzbacher I, Benesch T, Fodinger M, Sunder-Plassmann G, Haas M. Low-Turnover Bone Disease in Hypercalcemic Hyperparathyroidism After Kidney Transplantation. Am J Transplant. 2007 Nov; 7(1):2515–21. https://doi.org/10.1111/j.1600-6143.2007.01950.x PMID: 17725680

21. Lehmann G, Ott U, Stein G, Steiner T, Wolf G. Renal Osteodystrophy After Successful Renal Transplantation: A Histomorphometric Analysis in 57 Patients. Transplant Proc. 2007 Dec; 39(10):3153–58. https://doi.org/10.1016/j.transproceed.2007.10.001 PMID: 18089342

22. Neves C, dos Reis L, Batista D, Custodio M, Graciolli F, Martin RdC, et al. Persistence of Bone and Mineral Disorders 2 Years After Successful Kidney Transplantation. Transplantation. 2013 Aug 15; 96 (3):290–96. https://doi.org/10.1097/TP.Ob013e3182985468 PMID: 23823648

23. Carvalho C, Magalhães J, Pereira L, Simões-Silva L, Castro-Ferreira I, Frazão JM. Evolution of bone disease after kidney transplantation: A prospective histomorphometric analysis of trabecular and cortical bone. Nephrology. 2016 Jan; 21(1):55–61. https://doi.org/10.1111/nep.12570 PMID: 26201946

24. Evenepoel P, Behets GJ, Viena L, D’Haese PC. Bone histomorphometry in de novo renal transplant recipients indicates a further decline in bone resorption 1 year posttransplantation. Kidney Int 2017 Feb; 91(2):469–76. https://doi.org/10.1016/j.kint.2016.10.008 PMID: 27998642

25. Kowarik A, Templ M. (2016). Imputation with the R Package # VIM. J Stat Softw. 2016 Oct; 74(7), 1–16.
31. Marques IDB, Araújo MJ, Graciolli FG, Dos Reis LM, Pereira RMR, Alvarenga JC, et al. A Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year after Kidney Transplantation. J Am Soc Nephrol. 2019 Feb; 30(2):355–65. https://doi.org/10.1681/ASN.2018060656 PMID: 30606784

32. Nikkel LE, Mohan S, Zhang A, McMahon DJ, Boutroy S, Dube G, et al. Reduced Fracture Risk With Early Corticosteroid Withdrawal After Kidney Transplant. Am J Transplant. 2012 Mar; 12(3):649–59. https://doi.org/10.1111/j.1600-6143.2011.03872.x PMID: 22151430

33. Evenepoel P, Claeskens B, Laurent MR, Bammens B, Naesens M, et al. Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. Nephrol Dial Transplant. 2018 Oct; 35(4):697–705.

34. Ilmori S, Mori Y, Akita W, Kuyama T, Takada S, Asai T, et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients-a single-center cohort study. Nephrol Dial Transplant. 2012 Jan; 27(1):345–51. https://doi.org/10.1093/ndt/gfr317 PMID: 21652590

35. Naylor KL, Jamal SA, Zou G, McArthur E, Lam NN, Leslie WD, et al. Fracture Incidence in Adult Kidney Transplant Recipients. Transplantation 2016. Jan; 100(1):167–75. https://doi.org/10.1097/TP.0000000000000808 PMID: 26154389

36. Sharma AK, Toussaint ND, Elder GJ, Rajapakse CS, Holt SG, Baldock P, et al. Changes in bone microarchitecture following kidney transplantation-Beyond bone mineral density. Clin Transplant 2018 Sep; 32(9): e13347. https://doi.org/10.1111/ctr.13347 PMID: 29984421

37. Nickolas TL, Stein EM, Dworkowski E, Nishiya M, Zhang CA, et al. Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res. 2013 Aug; 28(8):1811–20. https://doi.org/10.1002/jbmr.1916 PMID: 23456850

38. Malluche HH, Monier-Faugere M-C, Blomquist G, Davenport DL. Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors. Osteoporos Int. 2017 Oct 9; 29(1):125–34. https://doi.org/10.1007/s00198-017-4228-4 PMID: 28993865

39. Sharma A, Toussaint N, Masterson R, Holt S, Rajapakse C, Ebeling P, et al. Deterioration of Cortical Bone Microarchitecture: Critical Component of Renal Osteodystrophy Evaluation. Am J Nephrol. 2018 May; 47(6):376–84. https://doi.org/10.1159/000489671 PMID: 29791896

40. Bouquegnau A, Salam S, Delanaye P, Eastell R, Khwaja A. Bone Disease after Kidney Transplantation. Clin J Am Soc Nephrol. 2016 Jul; 11(7):1282–96. https://doi.org/10.2215/CJN.11371015 PMID: 26912549

41. Cho M, Duan Z, Chamberlain C, Reynolds J, Ring M, Mannion R. Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism. Transplant Proc. 2010 Nov; 42(9):3554–58. https://doi.org/10.1016/j.transproceed.2010.06.027 PMID: 21094814

42. Susan M Ott. Cortical or Trabecular Bone: What’s the Difference? Am J Nephrol. 2018 May 22; 47 (6):373–75. https://doi.org/10.1159/000489672 PMID: 29788030

43. Evenepoel P, D Haese PC, Bacchetta J, Cannata-Andia J, Ferreira A, Haarhaus M, et al. Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative: a position paper. Nephrol Dial Transplant. 2017 Oct 1; 32(10):1608–13. https://doi.org/10.1093/ndt/gfw468 PMID: 28339949